Market Overview

UPDATE: Merck Upgraded by Morgan Stanley on Oncology Optimism

Related MRK
Roth Capital Upgrades ANI Pharmaceuticals To Buy On Valuation
Merck Announces New Data from KEYNOTE-028 Trial Evaluating KEYTRUDA Across Range of Cancer Types, Presented at 2015 ECC
Alexion, Vertex Steal Mo Stanley's Eyes From Gilead (Investor's Business Daily)

In a report released Monday, JP Morgan analyst David Risinger upgraded Merck (NYSE: MRK) from Underweight to Overweight with a price target of $60.

Risinger notes, "Mgmt is taking the right steps—cost cuts, R&D changes, and considering strategic action—to boost company's outlook." One of the driving catalysts that the report mentioned is MK-3475, an immuno-oncology candidate which Merck filed for approval a year earlier than expected.

MRK closed Friday at $51.98 and is currently up nearly 3% at the $53.37 level.

Latest Ratings for MRK

Sep 2015JP MorganMaintainsOverweight
Aug 2015JefferiesMaintainsHold
Aug 2015BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: News Upgrades Price Target Markets Analyst Ratings


Related Articles (MRK)

Get Benzinga's Newsletters